Nuri El-Azem1, Mario Pulido-Moran1,2, Cesar L Ramirez-Tortosa3, Jose L Quiles1,4, Francisca E Cara5, Pedro Sanchez-Rovira6, Sergio Granados-Principal1,7, MCarmen Ramirez-Tortosa8,9. 1. "José Mataix" Institute of Nutrition and Food Technology, Biomedical Research Centre, Health Sciences Technological Park, University of Granada, 18016, Armilla, Granada, Spain. 2. Department of Biochemistry and Molecular Biology II, University of Granada, 18016, Armilla, Granada, Spain. 3. Department of Pathological Anatomy, Hospital Complex of Jaén, Jaén, Spain. 4. Department of Physiology, University of Granada, Granada, Spain. 5. Department of Nanomedicine, Houston Methodist Research Institute, Houston, TX, USA. 6. Oncology Service, Jaen City Hospital, Jaén, Spain. 7. Methodist Cancer Center, Houston Methodist Hospital, Houston, TX, USA. 8. "José Mataix" Institute of Nutrition and Food Technology, Biomedical Research Centre, Health Sciences Technological Park, University of Granada, 18016, Armilla, Granada, Spain. mramirez@ugr.es. 9. Department of Biochemistry and Molecular Biology II, University of Granada, 18016, Armilla, Granada, Spain. mramirez@ugr.es.
Abstract
PURPOSE: The main objective of this study was to test the therapeutic potential of hydroxytyrosol and its combination with paclitaxel in breast cancer on oxidative stress status. METHODS: Impact on proliferation rates of different chemotherapy administration patterns was assayed in MCF-7 and MDA-MB-231 breast cancer cell lines. Breast tumor-bearing rats were randomly assigned to Control, Hydroxytyrosol, Paclitaxel and Paclitaxel plus hydroxytyrosol groups, for 6 weeks. Tumor volume, cell proliferation and several systemic oxidative stress parameters were measured. Anti-proliferative activity in vitro experiments was correlated with in vivo experiments. RESULTS: Combination group did significantly reduce tumor volume when compared with paclitaxel alone. Additionally, the combination improved the antioxidant status without compromising the antitumor activity of standard chemotherapy. CONCLUSION: These findings reveal for the first time that hydroxytyrosol is an active partner in combined therapies with paclitaxel against breast cancer. Combination with hydroxytyrosol would also ensure a less oxidative impact of chemotherapeutic drugs that could potentially improve patient wellness.
PURPOSE: The main objective of this study was to test the therapeutic potential of hydroxytyrosol and its combination with paclitaxel in breast cancer on oxidative stress status. METHODS: Impact on proliferation rates of different chemotherapy administration patterns was assayed in MCF-7 and MDA-MB-231 breast cancer cell lines. Breast tumor-bearing rats were randomly assigned to Control, Hydroxytyrosol, Paclitaxel and Paclitaxel plus hydroxytyrosol groups, for 6 weeks. Tumor volume, cell proliferation and several systemic oxidative stress parameters were measured. Anti-proliferative activity in vitro experiments was correlated with in vivo experiments. RESULTS: Combination group did significantly reduce tumor volume when compared with paclitaxel alone. Additionally, the combination improved the antioxidant status without compromising the antitumor activity of standard chemotherapy. CONCLUSION: These findings reveal for the first time that hydroxytyrosol is an active partner in combined therapies with paclitaxel against breast cancer. Combination with hydroxytyrosol would also ensure a less oxidative impact of chemotherapeutic drugs that could potentially improve patient wellness.
Entities:
Keywords:
Breast cancer; Cell proliferation; Hydroxytyrosol; Multimodal treatment and paclitaxel; Oxidative stress
Authors: Jose M Romero-Márquez; María D Navarro-Hortal; Victoria Jiménez-Trigo; Pedro Muñoz-Ollero; Tamara Y Forbes-Hernández; Adelaida Esteban-Muñoz; Francesca Giampieri; Irene Delgado Noya; Pedro Bullón; Laura Vera-Ramírez; Maurizio Battino; Cristina Sánchez-González; José L Quiles Journal: Antioxidants (Basel) Date: 2022-03-25
Authors: Cesar Ramirez-Tortosa; Ana Sanchez; Cristina Perez-Ramirez; Jose Luis Quiles; María Robles-Almazan; Mario Pulido-Moran; Pedro Sanchez-Rovira; MCarmen Ramirez-Tortosa Journal: Antioxidants (Basel) Date: 2019-09-11
Authors: Carmen Griñan-Lison; Jose L Blaya-Cánovas; Araceli López-Tejada; Marta Ávalos-Moreno; Alba Navarro-Ocón; Francisca E Cara; Adrián González-González; Jose A Lorente; Juan A Marchal; Sergio Granados-Principal Journal: Antioxidants (Basel) Date: 2021-01-31
Authors: Jesús Calahorra; Esther Martínez-Lara; José M Granadino-Roldán; Juan M Martí; Ana Cañuelo; Santos Blanco; F Javier Oliver; Eva Siles Journal: Sci Rep Date: 2020-04-14 Impact factor: 4.379